{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:53:58Z","timestamp":1775562838951,"version":"3.50.1"},"reference-count":105,"publisher":"Edizioni Minerva Medica","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Minerva Med"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.23736\/s0026-4806.23.08509-9","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T10:36:06Z","timestamp":1686306966000},"source":"Crossref","is-referenced-by-count":8,"title":["Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update"],"prefix":"10.23736","volume":"114","author":[{"given":"Mohd","family":"WAHID","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad","family":"JAWED","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju K.","family":"MANDAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Y.","family":"AREESHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahed A.","family":"EL-SHALL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjan K.","family":"MOHAPATRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardeep S.","family":"TULI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldeep","family":"DHAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinaldo","family":"PELLICANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila","family":"FAGOONEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafiul","family":"HAQUE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17149","reference":[{"key":"10.23736\/S0026-4806.23.08509-9_ref001","unstructured":"WHO. 2021a. Coronavirus disease (COVID-19): Vaccines. WHO-Int. updated on 29 Nov, 2021; 2023 [Internet]. Available from: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-(covid-19)-vaccines [cited 2022, Jan 1]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref002","unstructured":"WHO. (2022a). DRAFT landscape of COVID-19 candidate vaccines; 2023 [Internet]. Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines [cited 2022, Feb 2]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref003","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.20.07054-8"},{"key":"10.23736\/S0026-4806.23.08509-9_ref004","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-542X.21.02765-8"},{"key":"10.23736\/S0026-4806.23.08509-9_ref005","unstructured":"WHO-int. Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness. June-2021."},{"key":"10.23736\/S0026-4806.23.08509-9_ref006","unstructured":"Vaccine efficacy, effectiveness and protection; 2023 [Internet]. Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/vaccine-efficacy-effectiveness-and-protection [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref007","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088"},{"key":"10.23736\/S0026-4806.23.08509-9_ref008","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.21.04286-5"},{"key":"10.23736\/S0026-4806.23.08509-9_ref009","unstructured":"The Immunization Advisory Centre. Efficacy and effectiveness. The University of Auckland Grafton Campus, Auckland, New Zealand; 2021 [Internet]. Available from: https:\/\/www.immune.org.nz\/vaccines\/efficiency-effectiveness [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref010","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.05.022"},{"key":"10.23736\/S0026-4806.23.08509-9_ref011","doi-asserted-by":"publisher","DOI":"10.1177\/15353702211014146"},{"key":"10.23736\/S0026-4806.23.08509-9_ref012","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1963601"},{"key":"10.23736\/S0026-4806.23.08509-9_ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2022.112816"},{"key":"10.23736\/S0026-4806.23.08509-9_ref014","unstructured":"WHO. (2021b). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, 26 November 2021; [Internet]. Available from: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern [cited 2022, Jan 3]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref015","unstructured":"WHO. (2022b). WHO Coronavirus (COVID-19) Dashboard. WHO COVID-19 Dashboard - Up to date data on pandemic; [Internet]. Available from: https:\/\/covid19.who.int\/?gclid=CjwKCAiA65iBBhB-EiwAW253W0GZ9U6T Bkdh4YsVuarVQDugzsyLRuZF-ctQMSaXK8Lcz9kZ14J9kRoC7uAQAvD_BwE [cited 2022, Feb 2]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref016","unstructured":"WHO. (2022c). World Health Organization. Tracking SARS-CoV-2 variants; 2022 [Internet]. Available from: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants [cited 2022, Feb 2]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref017","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106355"},{"key":"10.23736\/S0026-4806.23.08509-9_ref018","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070993"},{"key":"10.23736\/S0026-4806.23.08509-9_ref019","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab895"},{"key":"10.23736\/S0026-4806.23.08509-9_ref020","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101303"},{"key":"10.23736\/S0026-4806.23.08509-9_ref021","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27376"},{"key":"10.23736\/S0026-4806.23.08509-9_ref022","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27610"},{"key":"10.23736\/S0026-4806.23.08509-9_ref023","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101146"},{"key":"10.23736\/S0026-4806.23.08509-9_ref024","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e4"},{"key":"10.23736\/S0026-4806.23.08509-9_ref025","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00017-4"},{"key":"10.23736\/S0026-4806.23.08509-9_ref026","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00056-3"},{"key":"10.23736\/S0026-4806.23.08509-9_ref027","unstructured":"Worldmeter COVID-19 Coronavirus pandemic; 2022 [Internet]. Available from: https:\/\/www.worldometers.info\/coronavirus\/ [cited 2022, Feb 2]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref028","doi-asserted-by":"crossref","unstructured":"Katella K. Comparing the COVID-19 Vaccines: How Are They Different? Yale Medicine; 2021 [Internet]. Available from: https:\/\/www.yalemedicine.org\/news\/covid-19-vaccine-comparison [cited 2023, Apr 13].","DOI":"10.12816\/0059056"},{"key":"10.23736\/S0026-4806.23.08509-9_ref029","unstructured":"GAVI. The Vaccine Alliance. There are four types of COVID-19 vaccines: here's how they work, 2021."},{"key":"10.23736\/S0026-4806.23.08509-9_ref030","unstructured":"Corum J, Zimmer C. How the Sinovac Vaccine Works. The New York Times; 2021 [Internet]. Available from: https:\/\/www.nytimes.com\/interactive\/2020\/health\/sinovac-covid-19-vaccine.html [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref031","unstructured":"Zimmer C, Corum J, Wee SL. \"Coronavirus Vaccine Tracker\". The New York Times; 2021 [Internet]. Available from: https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref032","unstructured":"WHO. 2021d. Recommendation for an EUL of COVID-19 vaccine BIBP submitted by the BIBP Co., Ltd; 2021 [Internet]. Available from: https:\/\/extranet.who.int\/pqweb\/file\/bibppegtageulreportfinal04june21pdf [cited 2022, Jan 1]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref033","doi-asserted-by":"crossref","unstructured":"Al Qahtani M, Bhattacharyya S, Alawadi A, Al Mahmeed H, Al Sayed J, Justman J, et al. Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain; 2022 [Internet]. Available from: https:\/\/www.researchsquare.com\/article\/rs-828021\/v1 [cited 2022, Jan 1].","DOI":"10.21203\/rs.3.rs-828021\/v1"},{"key":"10.23736\/S0026-4806.23.08509-9_ref034","unstructured":"WHO. 2021c. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm Interim guidance; 2021 [Internet]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP [cited 2022, Jan 1]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref035","first-page":"1","article-title":"Inhibition of receptor-binding domain-ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca\/Oxford's AZD1222 SARS-CoV-2 vaccines","volume":"1","author":"Silva VO","year":"2021","journal-title":"J Med Virol"},{"key":"10.23736\/S0026-4806.23.08509-9_ref036","unstructured":"WHO. \u200e2021e\u200e. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance; 2021 [Internet]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/346788 [cited 2022, Jan 2]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107715"},{"key":"10.23736\/S0026-4806.23.08509-9_ref038","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742914"},{"key":"10.23736\/S0026-4806.23.08509-9_ref039","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2021.126"},{"key":"10.23736\/S0026-4806.23.08509-9_ref040","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102298"},{"key":"10.23736\/S0026-4806.23.08509-9_ref041","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30942-7"},{"key":"10.23736\/S0026-4806.23.08509-9_ref042","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.05.447177"},{"key":"10.23736\/S0026-4806.23.08509-9_ref043","unstructured":"WHO. 2021f. Background document on the Bharat Biotech BBV152 COVAXIN\u00ae vaccine against COVID-19.3 November 2021. Accessed on 02 Jan. 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin-background"},{"key":"10.23736\/S0026-4806.23.08509-9_ref044","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"10.23736\/S0026-4806.23.08509-9_ref045","unstructured":"Different types of COVID-19 vaccines: How they work. COVID-19: Advice, updates and vaccine options. Mayo Foundation for Medical Education and Research (MFMER); 2021 [Internet]. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/coronavirus\/in-depth\/different-types-of-covid-19-vaccines\/art-20506465 [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref046","unstructured":"Kemp A. AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine; 2020 [Internet]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref047","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.5.2509"},{"key":"10.23736\/S0026-4806.23.08509-9_ref048","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2004.08.014"},{"key":"10.23736\/S0026-4806.23.08509-9_ref049","doi-asserted-by":"publisher","DOI":"10.3390\/v2081681"},{"key":"10.23736\/S0026-4806.23.08509-9_ref050","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385"},{"key":"10.23736\/S0026-4806.23.08509-9_ref051","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2020.105778"},{"key":"10.23736\/S0026-4806.23.08509-9_ref052","unstructured":"Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR. European Medicines Agency (EMA); 2021 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria-previously-covid-19-vaccine-astrazeneca [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref053","unstructured":"AstraZeneca vaccine renamed 'Vaxzevria'\"; 2021 [Internet]. Available from: https:\/\/www.brusselstimes.com\/news\/eu-affairs\/162559\/astrazeneca-vaccine-now-renamed-as-vaxzevria-ema-european-eu-uk-swedish-lakemedelsverket [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref054","first-page":"695","article-title":"COVID vaccine's hot problems: erratic serious blood clotting, ill-defined prion-like reactogenicity of the spike, unclear roles of other factors","volume":"112","author":"Actis GC","year":"2021","journal-title":"Minerva Med"},{"key":"10.23736\/S0026-4806.23.08509-9_ref055","unstructured":"Belluz J. Why the AstraZeneca-Oxford Covid-19 vaccine is different, 2020. Vox.; 2021 [Internet]. Available from: https:\/\/www.vox.com\/21590994\/oxford-vaccine-results-covid-19-astrazeneca-trial-pfizer-moderna [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref056","unstructured":"Vaccine C. Summary of Yellow Card Reporting-It is known from the clinical trials that the more common side effects for both vaccines can occur at a rate of more than one in 10 doses (for example, local reactions or symptoms resembling transient flu-like symptoms), 2021. MHRA: 1-30."},{"key":"10.23736\/S0026-4806.23.08509-9_ref057","unstructured":"AstraZeneca's COVID-19 vaccine: benefits and risks in context\". European Medicines Agency (EMA); 2021 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-benefits-risks-context [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref058","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.01.21252652"},{"key":"10.23736\/S0026-4806.23.08509-9_ref059","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2113864"},{"key":"#cr-split#-10.23736\/S0026-4806.23.08509-9_ref060.1","unstructured":"COVID-19 Vaccine AstraZeneca Real-World Evidence Summary. AstraZeneca, 2021 (24-December"},{"key":"#cr-split#-10.23736\/S0026-4806.23.08509-9_ref060.2","unstructured":"2021 [Internet]. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/viewer.html?pdfurl=https%3A%2F%2Fwww.astrazeneca.com%2Fcontent%2Fdam%2Faz%2Fcovid-19%2Fmedia%2Ffactsheets%2FCOVID-19_Vaccine_AstraZeneca_Real-World_Evidence_Summary.pdf&amp;clen=696334&amp;chunk=true [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref061","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.11.011"},{"key":"10.23736\/S0026-4806.23.08509-9_ref062","unstructured":"Browne R. What you need to know about BioNTech - the European company behind Pfizer's Covid-19 vaccine. CNBC; 2021 [Internet]. Available from: https:\/\/www.cnbc.com\/2020\/11\/11\/biontech-the-european-company-behind-pfizers-covid-19-vaccine.html [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref063","unstructured":"Recommends Pediatric CD. COVID-19 Vaccine for Children 5 to 11 Years. U.S. Centers for Disease Control and Prevention (CDC); 2021 [Internet]. Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/planning\/children.html [cited 2023, Apr 13]."},{"key":"#cr-split#-10.23736\/S0026-4806.23.08509-9_ref064.1","unstructured":"FDA. 2021. Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds"},{"key":"#cr-split#-10.23736\/S0026-4806.23.08509-9_ref064.2","unstructured":"2021 [Internet]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17 [cited 2022, Jan 1]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref065","unstructured":"Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY) Overview and Safety. U.S. Centers for Disease Control and Prevention (CDC); 2021 [Internet]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/Pfizer-BioNTech.html [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref066","unstructured":"Moderna COVID-19 Vaccine - cx-024414 injection, suspension. DailyMed, 2020; 2021 [Internet]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e0651c7a-2fe2-459d-a766-0d59e919f058 [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref067","unstructured":"Spikevax (previously COVID-19 Vaccine Moderna) EPAR. European Medicines Agency (EMA); 2021 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref068","unstructured":"Moderna COVID-19 vaccine\". Health Canada, 2020; 2021 [Internet]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/moderna.html [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref069","unstructured":"'Significant increase' in protection vs Omicron from mRNA boosters, study says. Reuters; 2021 [Internet]. Available from: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/significant-increase-protection-vs-omicron-mrna-boosters-study-says-2021-12-22\/ [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref070","unstructured":"TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group. Therapeutic Goods Administration (TGA); 2021 [Internet]. Available from: https:\/\/www.tga.gov.au\/media-release\/tga-provisional-approval-moderna-covid-19-vaccine-include-12-17-years-age-group [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref071","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"10.23736\/S0026-4806.23.08509-9_ref072","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.2927"},{"key":"10.23736\/S0026-4806.23.08509-9_ref073","unstructured":"Janssen COVID-19 Vaccine-ad26.cov2. s injection, suspension. DailyMed. U.S. National Institutes of Health; 2021 [Internet]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=14a822ff-f353-49f9-a7f2-21424b201e3b [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref074","unstructured":"Regulatory approval of COVID-19 Vaccine Janssen. Medicines and Healthcare products Regulatory Agency (MHRA); 2021 [Internet]. Available from: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-janssen) [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref075","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267615"},{"key":"10.23736\/S0026-4806.23.08509-9_ref076","unstructured":"The COVID-19 vaccine race - weekly update. Gavi-The Vaccine Alliance[cited 2021, Dec 30].https:\/\/www.gavi.org\/vaccineswork\/covid-19-vaccine-race [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref077","unstructured":"Lovelace B Jr, Miller SG. 2021.CDC recommends people not get J&amp;J vaccine if Pfizer, Moderna are available; 2021 [Internet]. Available from: https:\/\/www.nbcnews.com\/health\/health-news\/cdc-panel-recommends-people-not-get-jj-vaccine-pfizer-moderna-availabl-rcna8987 [cited 2021, Dec 30]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref078","unstructured":"Smith P. 2021b. Johnson &amp; Johnson's booster offers strong protection against hospitalization, South African study shows; 2021 [Internet]. Available from:https:\/\/www.nbcnews.com\/news\/world\/johnson-johnsons-booster-offers-strong-protection-hospitalization-sout-rcna10401 [cited 2021, Dec 30]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref079","unstructured":"Smith A. 2021a. Omicron appears more resistant to Covid vaccines but is causing less severe illness in South Africa, major study finds; 2021 [Internet]. Available from:https:\/\/www.nbcnews.com\/news\/world\/omicron-covid-variant-resistant-pfizer-vaccine-south-africa-rcna8678 [cited 2021, Dec 30]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref080","unstructured":"Moderna COVID-19 Vaccine Overview and Safety. Centers for Disease Control and Prevention (CDC); 2021 [Internet]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/Moderna.html) [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref081","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068848"},{"key":"10.23736\/S0026-4806.23.08509-9_ref082","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.473584"},{"key":"10.23736\/S0026-4806.23.08509-9_ref083","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27561"},{"key":"10.23736\/S0026-4806.23.08509-9_ref084","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27585"},{"key":"10.23736\/S0026-4806.23.08509-9_ref085","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27633"},{"key":"10.23736\/S0026-4806.23.08509-9_ref086","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e3"},{"key":"10.23736\/S0026-4806.23.08509-9_ref087","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.801431"},{"key":"10.23736\/S0026-4806.23.08509-9_ref088","unstructured":"Edward E. 2021. A key component of the J&amp;J vaccine could explain the risk of extremely rare blood clots; 2021 [Internet]. Available form: https:\/\/www.nbcnews.com\/health\/health-news\/key-component-j-j-vaccine-could-explain-risk-extremely-rare-n1263939 [cited 2021, Dec 30]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref089","unstructured":"Molnupiravir. Science, Coronavirus Drug and Treatment Tracker, The New York Times-2021; 2021 [Internet]. Available form: https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-drugs-treatments.html?auth=link-dismiss-google1tap#molnupiravir [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref090","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.720"},{"key":"10.23736\/S0026-4806.23.08509-9_ref091","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00094-0"},{"key":"10.23736\/S0026-4806.23.08509-9_ref092","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac005"},{"key":"10.23736\/S0026-4806.23.08509-9_ref093","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00837-6"},{"key":"10.23736\/S0026-4806.23.08509-9_ref094","unstructured":"Kalter L. CDC: Boosters Key in Protecting Against Omicron; 2021 [Internet]. Available form: https:\/\/www.webmd. com\/vaccines\/covid-19-vaccine\/news\/20211210\/boosters-key-for-omicron [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref095","unstructured":"Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. U.S. Food &amp; Drug Administration; 2021 [Internet]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref096","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.22000001"},{"key":"10.23736\/S0026-4806.23.08509-9_ref097","unstructured":"Zimmer C, Wu KJ, Corum J, Kristoffersen M. Coronavirus Drug and Treatment Tracker. The New York Times; 2021 [Internet]. Available from: https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-drugs-treatments.html?auth=link-dismiss-google1tap#azd7442 [cited 2023, Apr 13]."},{"key":"10.23736\/S0026-4806.23.08509-9_ref098","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241165"},{"key":"10.23736\/S0026-4806.23.08509-9_ref099","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101052"},{"key":"10.23736\/S0026-4806.23.08509-9_ref100","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.10.21267534"},{"key":"10.23736\/S0026-4806.23.08509-9_ref101","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-542X.21.02742-7"},{"key":"10.23736\/S0026-4806.23.08509-9_ref102","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-542X.20.02659-2"},{"key":"10.23736\/S0026-4806.23.08509-9_ref103","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-542X.20.02652-X"}],"container-title":["Minerva Medica"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R10Y2023N05A0683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T07:52:57Z","timestamp":1700207577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R10Y2023N05A0683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":105,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.23736\/s0026-4806.23.08509-9","relation":{},"ISSN":["0026-4806","1827-1669"],"issn-type":[{"value":"0026-4806","type":"print"},{"value":"1827-1669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}